HER2 Testing Market Size & Share, by Technique (Immunohistochemistry (IHC) Test, Fluorescence in Situ Hybridization, Chromogenic in Situ Hybridization, Silver-Enhanced in Situ Hybridization); Cancer Type (Breast Cancer, Gastric Cancer, Bladder Cancer, Ovarian Cancer); End Users (Hospital, Diagnostic Centers, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5626
  • Published Date: Feb 12, 2024
  • Report Format: PDF, PPT

Companies Dominating the HER2 Testing Market

top-features-companies
    • Agilent Technologies, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Thermo Fisher Scientific
    • Roche
    • Empire Genomics Inc.
    • Abnova Corporation
    • Eli Lilly and Company
    • Oxford Gene Technology IP Limited
    • Genetech
    • Genemed Technologies Inc.
    • PERKINELMER Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Roche announced that the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody has received approval from the U.S. FDA. When a patient has low HER2 expression, this antibody can be used to identify them and assist assess whether Enhertu is a good targeted treatment choice for them.
  • Eli Lilly and Company declared that the expanded use of Verzenio (abemaciclib) in conjunction with endocrine therapy (ET) has received approval from the U.S. FDA. Adjuvant treatment for adult patients with hormone receptor-positive (HR+), HER2-negative, node-positive early breast cancer (EBC) who are at high risk of recurrence is now permitted with this approval.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5626
  • Published Date: Feb 12, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing research and development in cancer diagnostic technologies and the popularity of HER2 testing for breast cancer screening are the major factors driving the growth of the HER2 testing market.

The market size of HER2 testing is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market are Thermo Fisher Scientific, Roche, Empire Genomics Inc., Abnova Corporation, Eli Lilly and Company, Oxford Gene Technology IP Limited, Genetech, Genemed Technologies Inc., PERKINELMER Inc., and others.

The breast cancer segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying